Sick of high drug prices, insurers join hospitals to make their own generic medications

23 January 2020 - Everyone complains about high drug prices. But hospitals — and now insurers — are trying to ...

Read more →

European Commission approves Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are transplant eligible

20 January 2020 - Janssen announced today that the European Commission has granted marketing authorisation for Darzalex  (daratumumab) in combination with ...

Read more →

Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea

20 January 2020 - Sunosi is the only licensed therapy in Europe for the treatment of excessive daytime sleepiness in adults ...

Read more →

After 20 years of using economic evaluation, should NICE be considered a methods innovator?

13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...

Read more →

Talkin’ about a resolution: issues in the push for greater transparency of medicine prices

20 January 2020 - At the 2019 World Health Assembly, a significant new resolution was agreed by most countries to start ...

Read more →

FDA delays decision on Intercept's NASH drug by three months

20 January 2020 - Action date pushed back to 26 June. ...

Read more →

Patients still struggle to balance high costs of MS treatment, despite generic

20 January 2020 - Sometimes, the approval of a new generic drug offers more hype than hope for patients' wallets, ...

Read more →

Novartis announces EU approval of Mayzent (siponimod) for adult patients with secondary progressive multiple sclerosis with active disease

20 January 2020 - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple ...

Read more →

Lynparza regulatory submission granted priority review in the US for HRR-mutated metastatic castration-resistant prostate cancer

20 January 2020 - Submission based on PROfound, the first positive Phase III trial testing a targeted treatment in biomarker-selected ...

Read more →

Ten recommendations to unlock the potential of big data for public health in the EU

20 January 2020 - The joint Big Data Task Force of EMA and the Heads of Medicines Agencies proposes ten ...

Read more →

Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study

17 January 2020 - Failure to report the results of a clinical trial can distort the evidence base for clinical practice, ...

Read more →

Fees and charges proposal 2020-21

20 January 2020 - The TGA is undertaking a consultation through its website to seek stakeholder's views on TGA’s proposed fees ...

Read more →

Why cancelling your private health insurance could have unintended consequences

20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...

Read more →

New fee website shows NSW pays up to 40 times more in out-of-pocket costs

20 January 2020 - Private health patients in NSW are paying up to 40 times more in out-of-pocket costs than ...

Read more →

Sharing health care data with digital giants

16 January 2020 - Overcoming obstacles and reaping benefits while protecting patients. ...

Read more →

New science strategy prepares regulatory scientists for the future

20 January 2020 - The Health Products Regulation Group in the Department of Health has published a new regulatory science ...

Read more →